Liposome-encapsulated hemoglobin (hemoglobin-vesicle) is not transferred from mother to fetus at the late stage of pregnancy in the rat model

Kaga, Maiko; Li, Heng; Ohta, Hidenobu; Taguchi, Kazuaki; Ogaki, Shigeru; Izumi, Hitomi; Inagaki, Masumi; Tsuchiya, Shigeru; Okamura, Koji; Otagiri, Masaki; Sakai, Hiromi; Yaegashi, Nobuo

doi:10.1016/j.lfs.2012.08.021

Cited by 17 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disposition of HbV for use in pregnant mothers and fetuses has also been investigated [112]. Pregnant rats were given daily repeated injections of HbV (2000 mg/kg) from days 16 to 22 of pregnancy.…”

Section: Cellular Type Hbocsmentioning

confidence: 99%

Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers

Taguchi

Yamasaki

Maruyama

et al. 2017

JFB

Self Cite

View full text Add to dashboard Cite

Hemoglobin (Hb) is an ideal material for use in the development of an oxygen carrier in view of its innate biological properties. However, the vascular retention of free Hb is too short to permit a full therapeutic effect because Hb is rapidly cleared from the kidney via glomerular filtration or from the liver via the haptogloblin-CD 163 pathway when free Hb is administered in the blood circulation. Attempts have been made to develop alternate acellular and cellular types of Hb based oxygen carriers (HBOCs), in which Hb is processed via various routes in order to regulate its pharmacokinetic properties. These HBOCs have been demonstrated to have superior pharmacokinetic properties including a longer half-life than the Hb molecule in preclinical and clinical trials. The present review summarizes and compares the pharmacokinetic properties of acellular and cellular type HBOCs that have been developed through different approaches, such as polymerization, PEGylation, cross-linking, and encapsulation.

show abstract

Section: Cellular Type Hbocsmentioning

confidence: 99%

Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers

Taguchi

Yamasaki

Maruyama

et al. 2017

JFB

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this model, we hypothesize that continuous intravenous administration of hemoglobin vesicle (HbV), when added to an L-NAME-induced state of chronic NO inhibition during pregnancy, will treat placental and fetal hypoxia and improve fetal development. In this study, we applied to the pre-eclampsia model rat a daily HbV dose of 200 mg/kg/day, which has been proven to be the most effective and safe dosage to rescue hypoxic tissues in animal models in previous studies 4 5 8 .…”

mentioning

confidence: 99%

Artificial oxygen carriers rescue placental hypoxia and improve fetal development in the rat pre-eclampsia model

Ohta

Tahara

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

Pre-eclampsia affects approximately 5% of all pregnant women and remains a major cause of maternal and fetal morbidity and mortality. The hypertension associated with pre-eclampsia develops during pregnancy and remits after delivery, suggesting that the placenta is the most likely origin of this disease. The pathophysiology involves insufficient trophoblast invasion, resulting in incomplete narrow placental spiral artery remodeling. Placental insufficiency, which limits the maternal-fetal exchange of gas and nutrients, leads to fetal intrauterine growth restriction. In this study, in our attempt to develop a new therapy for pre-eclampsia, we directly rescued placental and fetal hypoxia with nano-scale size artificial oxygen carriers (hemoglobin vesicles). The present study is the first to demonstrate that artificial oxygen carriers successfully treat placental hypoxia, decrease maternal plasma levels of anti-angiogenic proteins and ameliorate fetal growth restriction in the pre-eclampsia rat model.

show abstract

“…According to numerous animal studies, Hb-V potentially exhibits a favorable safety profile, including blood compatibility (no platelet and complement activation) and lack of tissue damage, nephrotoxicity, and hypertension, even if repeatedly administered at high doses. 3) Furthermore, as summarized in Table 1, it exhibited well-defined pharmacokinetic characteristics such as blood retention; distribution, metabolic, and excretion profiles; the influence of accelerated blood clearance phenomenon; and drug-interaction with CYP [6][7][8][9][10][11][12][13][14][15][16][17] . On the basis of accumulated evidence, some basic research has been conducted to investigate the possibility that Hb-V can be applied as an oxygen carrier against various ischemic or hypoxic disorders such as hemorrhagic shock, 18) brain ischemia, 19) and pre-eclampsia.…”

Section: Hemoglobin Vesicles (Hb-v)mentioning

confidence: 99%

Pharmaceutical Technology Innovation Strategy Based on the Function of Blood Transport Proteins as DDS Carriers for the Treatment of Intractable Disorders and Cancer

Taguchi

2020

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Blood transport proteins are biogenic molecules with unique and interesting inherent characteristics that make up living organisms. As the utilization of their inherent characteristics can be a groundbreaking strategy to resolve and improve several clinical problems, attempts have been made to develop pharmaceutical and biomedical preparations based on blood transport proteins for the treatment and diagnosis of disorders. Among various blood transport proteins, we focus on the immense potential of hemoglobin and albumin to serve as carriers of biomedical gases (oxygen and carbon monoxide) and anticancer agents (lowmolecular compounds and antisense oligodeoxynucleotides), respectively, for the development of innovative drug delivery systems (DDS) to treat intractable disorders and solid cancers. In this review, I introduce the pharmaceutical technology, strategies, and application of DDS carriers that have been designed on the basis of the structure and function of hemoglobin and albumin. In addition, the prospect of using hemoglobin and albumin as materials for DDS carriers is discussed.

show abstract

Liposome-encapsulated hemoglobin (hemoglobin-vesicle) is not transferred from mother to fetus at the late stage of pregnancy in the rat model

Cited by 17 publications

References 27 publications

Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers

Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers

Artificial oxygen carriers rescue placental hypoxia and improve fetal development in the rat pre-eclampsia model

Pharmaceutical Technology Innovation Strategy Based on the Function of Blood Transport Proteins as DDS Carriers for the Treatment of Intractable Disorders and Cancer

Contact Info

Product

Resources

About